This week's note from the instructor discusses operational considerations to make while implementing new billing processes for therapy assistant modifiers.
Chimeric antigen receptor T-cell (CAR-T) therapy provided to Medicare Advantage (MA) beneficiaries will be paid for by traditional Medicare for calendar years 2019 and 2020.